Skip to main content
Erschienen in: Pediatric Nephrology 12/2014

01.12.2014 | Brief Report

Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012

verfasst von: Morgan Finkel, Adam Goldstein, Yael Steinberg, Linda Granowetter, Howard Trachtman

Erschienen in: Pediatric Nephrology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Cisplatinum (CP) is associated with acute kidney injury. The aim of this study was to define the spectrum of CP-induced nephrotoxicity in current practice.

Case-Diagnosis/Treatment

A single-center, retrospective chart review was performed on children who received CP for treatment of a malignancy at the Hassenfeld Children’s Center for Blood and Cancer Disorders of NYU Langone Medical Center between 2005 and 2012. Patients were considered to have nephrotoxicity if they had: (1) a decrease in estimated glomerular filtration rate (eGFR) of ≥30 % or (2) a decline in serum magnesium of ≥0.2 meq/L or (3) a decline in serum potassium of ≥0.2 meq/L. Thirty-two patients (mean age 8.0 ± 7.0 years) were included in this review, of whom 21 had a brain tumor (BT) and 11 had an osteosarcoma (OS); 31 (97 %) of the patients had a disturbance in renal function. The mean reduction in eGFR, serum magnesium and potassium was 37 ± 17, 30 ± 16 and 25 ± 14 %, respectively. The decline in eGFR, hypomagnesemia and hypokalemia was persistent in 38, 60 and 40 % of cases, respectively, through the short-term follow-up period. No patients required dialysis.

Conclusions

Nearly all patients receiving CP in current care experience modest glomerular and tubular injury. The abnormalities persist in 40–60 % of cases during the short-term recovery period after CP treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Anninga JK, Gelderblom H, Fiocco M (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand. Eur J Cancer 47:2431–2445PubMedCrossRef Anninga JK, Gelderblom H, Fiocco M (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand. Eur J Cancer 47:2431–2445PubMedCrossRef
2.
Zurück zum Zitat Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ (2007) Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 48:278–284PubMedCrossRef Thorarinsdottir HK, Rood B, Kamani N, Lafond D, Perez-Albuerne E, Loechelt B, Packer RJ, MacDonald TJ (2007) Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 48:278–284PubMedCrossRef
3.
Zurück zum Zitat Brock PR, Koliouskas DE, Barratt TM, Yoemans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534PubMedCrossRef Brock PR, Koliouskas DE, Barratt TM, Yoemans E, Pritchard J (1991) Partial reversibility of cisplatin nephrotoxicity in children. J Pediatr 118:531–534PubMedCrossRef
4.
Zurück zum Zitat Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219PubMedCrossRef Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD (2009) Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. Eur J Cancer 45:3213–3219PubMedCrossRef
5.
Zurück zum Zitat Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682PubMedCrossRefPubMedCentral Skinner R, Pearson ADJ, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW (1998) Cisplatin dose rate as a risk factor for nephrotoxicity in children. Br J Cancer 77:1677–1682PubMedCrossRefPubMedCentral
6.
Zurück zum Zitat Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28:35–40PubMedCrossRef Ariceta G, Rodriguez-Soriano J, Vallo A, Navajas A (1997) Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol 28:35–40PubMedCrossRef
7.
Zurück zum Zitat Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124PubMedCrossRef Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124PubMedCrossRef
8.
Zurück zum Zitat Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCrossRefPubMedCentral Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCrossRefPubMedCentral
9.
Zurück zum Zitat Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E, Dubourg L, Monge M, Bergerot D, Baron S, Essig M, Bridoux F, Tack I, Azizi M (2014) Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol. doi:10.1681/ASN.2014030293 Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E, Dubourg L, Monge M, Bergerot D, Baron S, Essig M, Bridoux F, Tack I, Azizi M (2014) Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol. doi:10.​1681/​ASN.​2014030293
10.
Zurück zum Zitat Zareifar S, Jafari H, Geramizadeh B, Basiratnia M, Golafshan H, Cohan N, Mehravar Z, Hamidi R (2013) The evaluation of cisplatin effect on tubular function in children on chemotherapy. Pediatr Hematol Oncol 30:18–24PubMedCrossRef Zareifar S, Jafari H, Geramizadeh B, Basiratnia M, Golafshan H, Cohan N, Mehravar Z, Hamidi R (2013) The evaluation of cisplatin effect on tubular function in children on chemotherapy. Pediatr Hematol Oncol 30:18–24PubMedCrossRef
11.
Zurück zum Zitat Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16:3365–3370PubMedCrossRef Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16:3365–3370PubMedCrossRef
12.
13.
Zurück zum Zitat Pannu N (2013) Bidirectional relationships between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens 22:351–356PubMedCrossRef Pannu N (2013) Bidirectional relationships between acute kidney injury and chronic kidney disease. Curr Opin Nephrol Hypertens 22:351–356PubMedCrossRef
Metadaten
Titel
Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012
verfasst von
Morgan Finkel
Adam Goldstein
Yael Steinberg
Linda Granowetter
Howard Trachtman
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 12/2014
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-014-2935-z

Weitere Artikel der Ausgabe 12/2014

Pediatric Nephrology 12/2014 Zur Ausgabe

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.